相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
Sabine Vogler et al.
LANCET ONCOLOGY (2016)
Failures in Phase III: Causes and Consequences
Bostjan Seruga et al.
CLINICAL CANCER RESEARCH (2015)
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
Karl Claxton et al.
HEALTH TECHNOLOGY ASSESSMENT (2015)
First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis
Daniel A. Goldstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Do the Current Performance-Based Schemes in Italy Really Work? Success Fee: A Novel Measure for Cost-Containment of Drug Expenditure
Andrea Navarria et al.
VALUE IN HEALTH (2015)
Necitumumab in Metastatic Squamous Cell Lung Cancer Establishing a Value-Based Cost
Daniel A. Goldstein et al.
JAMA ONCOLOGY (2015)
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs
Sham Mailankody et al.
JAMA ONCOLOGY (2015)
Indication-Specific Pricing for Cancer Drugs
Peter B. Bach
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Cost Effectiveness and Cancer Drugs
Jodie E. Battley et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
Lee M. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud et al.
BLOOD (2013)
Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: US Food and Drug Administration Drug Approval Summary
Paul G. Kluetz et al.
CLINICAL CANCER RESEARCH (2013)
Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries
Christine Leopold et al.
HEALTH POLICY (2013)
HEALTH TECHNOLOGY ASSESSMENT, VALUE-BASED DECISION MAKING, AND INNOVATION
Chris Henshall et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2013)
The Just Price of Cancer Drugs and the Growing Cost of Cancer Care: Oncologists Need to Be Part of the Solution
David G. Pfister
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cancer Drugs in the United States: Justum Pretium-The Just Price
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Study finds different efficacy for afatinib in non-small-cell lung cancer cases with EGF receptor mutations
[Anonymous]
LUNG CANCER MANAGEMENT (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations
James Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Differences in external price referencing in Europe-A descriptive overview
Christine Leopold et al.
HEALTH POLICY (2012)
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Proposal for a Novel Methodology to Screen And Score Cost Versus Survival for Anticancer Drugs in Metastatic Disease: Could Cost Weigh in Evaluation?
Helmy M. Guirgis
JOURNAL OF ONCOLOGY PRACTICE (2012)
What principles should govern the use of managed entry agreements?
Marianne Klemp et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2011)
How much is the life of a cancer patient worth? A pharmaco-economic perspective
S. Simoens et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2011)
Bending the Cost Curve in Cancer Care
Thomas J. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers
Jakub Adamski et al.
BMC HEALTH SERVICES RESEARCH (2010)
Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
Josh J. Carlson et al.
HEALTH POLICY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective
C. McCabe et al.
ANNALS OF ONCOLOGY (2009)
How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
Tito Fojo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
分享论文
